Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 5

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 5
---
 and holders of Swedish Listed Shares, in the documentation made available to them.

#### 2.

#### Appointment of proxy
Holders of AstraZeneca Shares are entitled to appoint a proxy in respect of some or all of their AstraZeneca Shares and may also appoint more than one proxy, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by such holder. Holders of AstraZeneca Shares are encouraged to appoint a proxy regardless of whether they intend to attend the General Meeting and should refer to the Notes to the Notice of General Meeting in Part VII ( Notice of General Meeting ) of this document for further information regarding the applicable procedures to be followed and deadline for submission of their proxy appointment depending on how they hold AstraZeneca Shares. The lodging of a proxy appointment will not prevent you from voting at the General Meeting if you so wish.

Holders of AstraZeneca Shares entitled to vote at the General Meeting may appoint a proxy electronically in accordance with the procedures set out in the Notes to the Notice of General Meeting in Part VII ( Notice of General Meeting ) of this document.

Holders of AstraZeneca ADSs and holders of Swedish Listed Shares should refer to paragraphs 4 and 5 (respectively) for further details of the arrangements applicable to them.

#### 3.

#### Holders of AstraZeneca Shares in the CSN Facility
Holders of AstraZeneca Shares in the CSN Facility may vote on the day or submit voting instructions in advance of the General Meeting in accordance with the procedures set out in the Notes to the Notice of General Meeting in Part VII ( Notice of General Meeting ) of this document.

#### 4.

#### Holders of AstraZeneca ADSs
Registered holders of AstraZeneca ADSs will receive a separate proxy voting instruction card and meeting guide, which includes instructions on how to vote and participate in the General Meeting.

Holders of AstraZeneca ADSs should follow the voting instructions set out in the notice documents sent to them. AstraZeneca ADS holders are encouraged to vote in advance of the General Meeting through the ADR Depositary, although arrangements will be in place to facilitate voting during the General Meeting. Where AstraZeneca ADS holders have submitted voting instructions in advance, it will not be possible to vote, or change previously submitted voting instructions, during the General Meeting via the online platform. Therefore, any AstraZeneca ADS holder wishing to vote via the online platform during the General Meeting